Table 1 Clinical features of human endometrial cancer
| Â | Total | Low-risk | High-risk | Recurrence |
|---|---|---|---|---|
n (%) | 34 (100) | 7 (21) | 27 (79) | 7 (21) |
Age, mean (range) | 59 (38–78) | 58 (38–75) | 60 (45–78) | 56 (45–67) |
FIGO stage, n (%) | Â | Â | Â | Â |
I | 15 (44) | 7 (100) | 8 (30) | 1 (14) |
II | 3 (9) | 0 (0) | 3 (11) | 1 (14) |
III | 14 (41) | 0 (0) | 14 (52) | 3 (43) |
IV | 2 (6) | 0 (0) | 2 (7) | 2 (29) |
Grade, n (%) | Â | Â | Â | Â |
1 | 15 (44) | 5 (71) | 10 (37) | 0 (0) |
2 | 13 (38) | 2 (29) | 11 (41) | 6 (86) |
3 | 6 (18) | 0 (0) | 6 (22) | 1 (14) |
Lymphovascular space invasion, n (%) | Â | Â | Â | Â |
+ | 10 (29) | 0 (0) | 10 (37) | 2 (29) |
- | 24 (71) | 7 (100) | 17 (63) | 5 (71) |
MIR31, mean | 18.40 | 2.05 | 21.90 | 9.15 |
(range) | (0.15 - 284.06) | (0.33 - 5.98) | (0.15 - 284.06) | (0.70 - 27.77) |